Drugs Made in America Acquisition (NASDAQ:DMAAU) Trading Down 0.5% – Here’s What Happened

Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) shares traded down 0.5% on Wednesday . The company traded as low as $10.50 and last traded at $10.50. 100 shares traded hands during trading, a decline of 99% from the average session volume of 9,929 shares. The stock had previously closed at $10.55.

Drugs Made in America Acquisition Stock Down 0.5%

The business’s 50 day moving average price is $10.53 and its 200-day moving average price is $10.51.

Drugs Made in America Acquisition Company Profile

Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.

The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.